Sona Nanotech (CSE: SONA, OTCQB: SNANF) advances nanotechnology medication through its exclusive gold nanorods that assure to alter the face of cancer treatment. Sona Nanotech’s platform innovation leverages distinctively biocompatible gold nanorods (GNRs). Biocompatibility is essential to the application of nanotechnology in medication.
For the previous numerous years, Sona has actually been striving to establish and operationalize its biocompatible nanoparticle innovation for usage in targeted cancer treatment. The business is likewise establishing a targeted cancer treatment, leveraging its exclusive Targeted Hyperthermia Treatment (THT) to straight deal with cancer cells.
Sona’s GNRs are rod-shaped nanoparticles made from gold and determining from 10 to 100 nanometers in length. Produced by chemical synthesis, they straight attend to a number of the present constraints of medical nanoparticle innovations. In addition to making them appropriate for cancer treatment, this likewise opens their capacity for usage in in-vivo medical applications.
Business Emphasizes
- Canadian nanotechnology business, Sona Nanotech has actually established an extremely appealing brand-new innovation that leverages distinctively biocompatible gold nanorods.
- The business likewise plays an essential function in the improvement of photothermal medical treatments, especially made it possible for by the business’s acquisition of Siva Rehabs.
- This acquisition has actually permitted Sona to advance the advancement of Targeted Hypothermia Treatment, attending to a number of the threats with present cancer treatments– especially the damage they can trigger to other tissues.
- THT has actually currently shown efficient in lowering growths in little animal research studies. Sona’s preliminary target for the innovation will be colorectal cancer.
- Quick diagnostic tests represent the business’s other tactical location of focus, consisting of bovine tuberculosis detection and concussion screening.
- Future applications for Sona’s innovation might consist of:
- Targeted drug shipment
- Photothermal cosmetic treatment
- Cell imaging
- Extra exclusive screening options supported by third-party test advancement services.
- The business’s management and board of directors consist of knowledgeable experts from throughout the health care and biotechnology sectors.
- Sona has a clear roadmap to commercialization of its treatment approach, beginning with a near-term driver in big animal research studies before relocating to a human pilot. It likewise anticipates a De Novo path for medical gadgets.
This Sona Nanotech belongs to a paid financier education project *
Click on this link to get in touch with Sona Nanotech (CSE: SONA) to get a Financier Discussion